An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

Conditions: Healthy Participants, Pharmacokinetic Study

Sex: All

Ages: 18 Years – 65 Years

Healthy volunteers: Yes

Phase: PHASE1

Enrollment: 28

Sponsor: Angitia Incorporated Limited

Location: Los Angeles EPCU Glendale California

Summary

This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants

Eligibility Criteria

Inclusion Criteria: * Healthy males or females, aged 18 to 65 years * 25-hydroxyvitamin D ≥30 ng/mL and agree to taking calcium and vitamin D supplements during the study * Meet the criteria for Japanese, Chinese, or Caucasian ethnicity Exclusion Criteria: * Participating or have participated in another clinical trial within the past 6 months * Any bone fracture within the past 6 months * History of myocardial infarction or stroke within the past 12 months * Malignancy within the past 5 years * Current hyper- or hypocalcemia * Pregnant or breastfeeding women, or women planning to become pregnant during the study

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07361354). StuddyBuddy aggregates publicly available trial information.